Histogenics Corp. (HSGX) Given New $11.00 Price Target at Needham & Company LLC
Histogenics Corp. (NASDAQ:HSGX) had its price objective lifted by Needham & Company LLC from $8.00 to $11.00 in a research report sent to investors on Monday. They currently have a buy rating on the stock.
Other equities analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Histogenics Corp. from a hold rating to a buy rating and set a $3.25 price target on the stock in a report on Friday, August 26th. BTIG Research raised shares of Histogenics Corp. from a neutral rating to a buy rating and set a $3.50 price target on the stock in a report on Thursday, August 11th. Finally, William Blair downgraded shares of Histogenics Corp. from an outperform rating to a market perform rating in a report on Wednesday, September 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $7.65.
Shares of Histogenics Corp. (NASDAQ:HSGX) opened at 3.0701 on Monday. Histogenics Corp. has a 12 month low of $1.39 and a 12 month high of $5.71. The firm’s market capitalization is $40.74 million. The stock’s 50 day moving average is $2.87 and its 200 day moving average is $2.29.
Histogenics Corp. (NASDAQ:HSGX) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.01. During the same period in the prior year, the firm earned ($0.58) EPS. Equities research analysts forecast that Histogenics Corp. will post ($2.11) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Histogenics Corp. stock. First Republic Investment Management Inc. raised its stake in shares of Histogenics Corp. (NASDAQ:HSGX) by 315.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 48,455 shares of the company’s stock after buying an additional 36,784 shares during the period. First Republic Investment Management Inc. owned approximately 0.37% of Histogenics Corp. worth $111,000 at the end of the most recent reporting period. 38.63% of the stock is owned by institutional investors and hedge funds.
About Histogenics Corp.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.